knowledge -WSS

knowledge

author：focus 2025-09-27 10:04:44 - browse：3

Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going to move markets in 2024?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.

For more on what we cover, here’s the news on Dewpoint Therapeutics; here’s more on biotech in 2024; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Today's health inequities arise from racist U.S. history, say experts

explore

WSS

What health policies could hitch a ride on a spending bill?

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Alkermes shareholders re

Sports medicine is finally prioritizing gender equality

Weight loss drugs should be covered by insurers, AMA says

Walensky prepares to leave CDC — and Congress — behind

Wikipedia

knowledge

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

FDA reorg will put new emphasis on investigations, sources say

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Supreme Court strikes down use of affirmative action

Hollywood unions extend contract negotiations for actors

Supreme Court strikes down use of affirmative action

Activists slam private health insurers over coverage restrictions

Walensky prepares to leave CDC — and Congress — behind

23andMe had bad news about my health. I wish a person had delivered it

Healthy food access boosts outcomes in two studies

knowledge

CVS, Rite Aid closures threaten to worsen pharmacy deserts

After decades in use, heart stents finally beat placebo

Hepatitis C has a cure — but many Americans still lack access to it

Today's health inequities arise from racist U.S. history, say experts

Medical school prerequisites are outdated

Hepatitis C has a cure — but many Americans still lack access to it

hotspot

explore

hotspot

hotspot